{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=3", "query": { "intervention": "ABI-007(Abraxane)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 2444, "total_pages": 245, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T14:52:36.630Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00960297", "title": "Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2009-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2021-12-06", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 6, "location_summary": "Fort Lauderdale, Florida • Terre Haute, Indiana • Louisville, Kentucky + 3 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Terre Haute", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Portsmouth", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960297" }, { "nct_id": "NCT04539808", "title": "NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8", "Stage I Pancreatic Cancer American Joint Committee on Cancer v8", "Stage III Pancreatic Cancer American Joint Committee on Cancer v8", "Stage IV Pancreatic Cancer American Joint Committee on Cancer v8" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Losartan Potassium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2021-05-27", "completion_date": "2027-01-05", "has_results": true, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04539808" }, { "nct_id": "NCT00487669", "title": "Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-small Cell Lung Cancer" ], "interventions": [ { "name": "paclitaxel poliglumex, pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2006-10", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2014-01-09", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487669" }, { "nct_id": "NCT01276496", "title": "Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Estrogen Receptor Negative", "HER2/Neu Negative", "Male Breast Carcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Cilengitide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2010-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-03-15", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01276496" }, { "nct_id": "NCT00004173", "title": "Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004173" }, { "nct_id": "NCT00542451", "title": "Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Carcinoma of the Breast" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 406, "start_date": "2007-10", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 20, "location_summary": "San Francisco, California • Maywood, Illinois • Indianapolis, Indiana + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00542451" }, { "nct_id": "NCT06333951", "title": "Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Thoracic Tumors", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Anvumetostat", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 49, "start_date": "2024-09-17", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 26, "location_summary": "Bakersfield, California • Duarte, California • Los Angeles, California + 20 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06333951" }, { "nct_id": "NCT04175912", "title": "Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cholangiocarcinoma", "Metastatic Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Cholangiocarcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-03-16", "completion_date": "2027-09-03", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 419, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04175912" }, { "nct_id": "NCT01431794", "title": "Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "LDE225-600mg", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "LDE225-400mg", "type": "DRUG" }, { "name": "LDE225-800mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2011-12-27", "completion_date": "2018-11-05", "has_results": true, "last_update_posted_date": "2020-01-22", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431794" }, { "nct_id": "NCT03154294", "title": "Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "TAK-228", "type": "DRUG" }, { "name": "TAK-117", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avera McKennan Hospital & University Health Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2017-07-06", "completion_date": "2022-11-20", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-10-10T14:52:36.630Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03154294" } ] }